Kura Oncology Secures $135 Million Milestone Payment from Kyowa Kirin
Kura Oncology Inc. has completed the first U.S. commercial sale of KOMZIFTI™ (ziftomenib) after FDA approval, triggering a $135 million milestone payment from Kyowa Kirin under their collaboration agreement. The payment is expected by year-end. This news was generated by Public Technologies using AI and is for informational purposes only.
Kura Oncology Inc. announced the completion of the first U.S. commercial sale of KOMZIFTI™ (ziftomenib), following its FDA approval on November 13, 2025. This sale has triggered a $135 million milestone payment to Kura under its collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. Kura expects to receive the payment before the end of the year. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595053-en) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
